Evoke Pharma, Inc. (EVOK) News
Filter EVOK News Items
EVOK News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EVOK News Highlights
- 500 - Internal server error
- Over the past 15 days, the trend for EVOK's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest EVOK News From Around the Web
Below are the latest news stories about Evoke Pharma Inc that investors may wish to consider to help them evaluate EVOK as an investment opportunity.
Evoke Pharma Launches Gimoti® Patient and Physician Experience ProgramProgram intends to expand awareness and trial of GIMOTI among non-prescribing healthcare providersSOLANA BEACH, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the start of additional marketing initiatives focusing on the launch of a patient and physician experience program for GIMOTI, the Company’s nasal spray product for the relief of symptoms in acute and r |
Evoke Pharma, EVERSANA and The International Foundation for Gastrointestinal Disorders Announce Membership into IFFGD’s Industry CouncilExtends commitment toward supporting patients experiencing Diabetic Gastroparesis through focused collaborations and Sponsorship of the 30th Anniversary Digestive Health Virtual WalkSOLANA BEACH, Calif., CHICAGO, and MOUNT PLEASANT, S.C., June 29, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, EVERSANA™, a leading provider of global commercial services to the life science industry, and The I |
Evoke Pharma and EVERSANA Announce Positive Findings from Second GIMOTI® Market Research StudyResults demonstrate continued increased awareness and intent to prescribe GIMOTISOLANA BEACH, Calif. and CHICAGO, June 15, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, a leading provider of global commercial services to the life science industry, today announced positive findings from a second market research study conducted for GIMOTI® (metoclopramide) nasal spray. The stud |
Evoke Pharma Announces Issuance of a New U.S. Patent Covering Methods of Use for Gimoti®New patent expands intellectual property protection for nasal delivery of metoclopramide and is expected to be FDA Orange Book listed SOLANA BEACH, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the United States Patent and Trademark Office (USPTO) issued US patent No. 11,020,361 to the Company related to Gimoti® (metoclopramide) nasal spray. The patent |
Evoke Pharma and EVERSANA Launch Social Media Campaign for Gimoti® Nasal SprayEvoke is committed to meeting patients online, where they search for answers New campaign leverages Facebook to satisfy significant unmet need for education and community SOLANA BEACH, Calif. and CHICAGO, May 27, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, a leading provider of global commercial services to the life science industry, today announced the launch of wave 1 of an innovative social media campaign to reach patients directly with education about diabetic gastroparesis (DGP). The initial wave of this program launched with two Facebook pages, a GimotiTM branded Facebook page and a diabetic gastroparesis community Facebook page called DGP-n-Me: Diabetic Gast... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayWe're starting the day off right with a look at the biggest pre-market stock movers for Thursday with earnings backing much of that movement. |
Evoke Pharma, Inc. (NASDAQ:EVOK) Is Expected To Breakeven In The Near FutureWe feel now is a pretty good time to analyse Evoke Pharma, Inc.'s ( NASDAQ:EVOK ) business as it appears the company... |
Evoke Pharma, Inc. (EVOK) Reports Q4 Loss, Misses Revenue EstimatesEvoke Pharma, Inc. (EVOK) delivered earnings and revenue surprises of -125.00% and -98.08%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock? |
Evoke Pharma Reports Fourth Quarter and Full Year 2020 Financial ResultsEncouraging early traction from GIMOTI™ commercial launchSOLANA BEACH, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter ended December 31, 2020 and recent corporate developments. “Despite the challenges precipitated by the COVID-19 pandemic, 2020 proved to be a transformative year for Evoke as we initiated the commercial launch of GIMOTI™ for acute and recurrent diabetic gastroparesis with our commercial partner EVERSANA,” stated David A. Gonyer, R.Ph., President and CEO of Evoke Pharma. “We are encouraged by the early traction we are seeing in GIMOTI sales and the feedback we are receiving from g... |
Evoke Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021SOLANA BEACH, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that the Company is scheduled to release its fourth quarter and full year 2020 financial results on Thursday, March 11, 2021, after the market closes. Evoke will host a conference call on Thursday, March 11, 2021, at 4:30 p.m. ET to discuss the results. The dial-in numbers for the conference call are (877) 473-1186 for domestic callers and (918) 922-6138 for international callers. The conference ID number is 4193567. In addition, a telephonic replay of the call will be available until March 18, 2021. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404)... |